Higher body fat content at baseline in patients with ankylosing spondylitis (AS) is likely to weaken response to treatment with tumour necrosis factor-α (TNF-α) blockers, measured by the Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), suggests a recent study.
Etanercept therapy for a period of 5 years leads to small changes in serum lipid concentrations, which are inversely correlated with inflammatory markers, according to a recent study. Other cardiovascular disease (CVD) risk factors remain stable.
Compared with other types of spondyloarthritis (SpA), SpA associated with inflammatory bowel disease (IBD-SpA) has significantly less frequency of dactylitis, enthesitis and anterior uveitis (AU), a recent study has found.
Oral contraceptives may cut the risk of developing rheumatoid arthritis (RA), especially anticitrullinated protein antibodies (ACPA)-positive RA, a study has found. Furthermore, long duration of OC use protects against the risk of both ACPA-positive and ACPA-negative RA.
The presence of rheumatoid factor (RF) rather than anticyclic citrullinated peptide antibodies (anti-CCP) may predict 10-year cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA), a recent study has found.
It appears that patient-reported pain, stiffness and fatigue at baseline offer limited value for the prediction of changes in disease activity and activity limitation in early rheumatoid arthritis (RA), according to a recent study.
Scleroderma renal crisis (SRC) appears to be a rare complication in Thai patients with systemic sclerosis (SSc), but is associated with high mortality, according to a study. Digital gangrene, current prednisolone dose ≥15 mg/day, serum albumin <3 mg/dL and cardiac involvement are independently associated with SRC.
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.